In November last year after I took a position, the share price...

In November last year after I took a position, the share price fell 30% after an "update" announcement. After the market closed I rang PD and chatted at length about the technology. I called on average once every 6 weeks after that, and ended up buying more shares. Calling the company is the right thing to do if you want to hear the company point of view without the filter of ASX announcements, and also get extra information (not price sensitive but contextual, e.g.. PD told me about his role at Roche and the start of the home blood testing kits for diabetes market).

I agree with you now about the "trial" nature of the contract. I haven't phoned since the nViso license restructure because I felt risk was low and ASX updates are enough for me now.

Thanks for sharing the feedback.